Table 1 New antibiotics approved and/or in development
Drug | Antibiotic class | Spectrum of microbiological activity | Main clinical indication | Development phase |
|---|---|---|---|---|
BAL30072 | Monocyclic β-lactam | MDR P. aeruginosa Acinetobacter including metallo-ß-lactamases and enterobacteriaceae | NK | I |
BC-3781 | Pleuromutilin | Gram-positive, including MRSA | cSSSIs | II |
Besifloxacin | Quinolone | Gram-positive and Gram-negative | ophthalmicinfection | Approved by FDA |
Biapenem | Cerbpenem | Gram-negative and Gram-positive | RTI, UTI | II |
CB-182,804 | Polimyxin | MDR Gram-negative | NK | I |
Ceftarolinefosamil | Cephalosporin | Gram-positive | cSSSIs, CAP | Approved by FDA and EMA |
Ceftazidime/Avibactam | Cephalosporin + betalactamase-inhibitor | MDR P. aeruginosa and enterobacteriaceae, excluding metallo-ß-lactamases | cUTI, cSSTI, VAP | III |
Ceftobiprolemedocaril | Cephalosporin | Gram-positive | cSSTI, hospitalized CAP | III |
Ceftolozane/tazobactam | Cephalosporin + betalactamase-inhibitor | Gram-negative | cIAI, cUTIs, HAP, VAP | III |
Cethromycin | Ketolide | Gram-positive and Gram-negative | CAP | III |
Dalbavancin | Glycopeptide | Gram-positive | cSSTI | III |
Delafloxacin | Quinolone | Broad-spectrum including fluoroquinolone-resistant MRSA | cSSTI | II |
Doripenem | Carbapenem | Gram-negative | cUTIs, cIAIs, HAP, VAP | Approved by FDA and EMA |
Eravacycline | Tetracycline | Gram-negative but not Pseudomonas | cIAI | II |
JNJ-Q2 | Quinolone | Enhanced Gram-positive activity including fluoroquinolone-resistance-resistant MRSA | cSSSIs | II |
ME 1036 | Carbapenem | Gram-positive, including MRSA and VRE, and Gram-negatives such ESBL-strains but not P. aeruginosa | CAP | Preclinicaldevelopment |
ME1071 | Betalactamaseinhibitor | Gram-negative | I | |
MK-7655 | Betalactamaseinhibitor | Gram-negative | cIAI, cUTIs | II |
Nemonoxacin | Quinolone | Gram-positive and Gram-negative | CAP | III |
Omadacycline | Tetracycline | Gram-positive and Gram-negative | cSSSIs, CAP | III |
Oritavancin | Glycopeptide | Gram-positive, including MRSA, VRSA, VRE | cSSSIs | III |
Panipenem | Carbapenem | Gram-negative and positive | cUTIs, RTI, obstetrical and gynaecological infections | III |
Plazomicin | Aminoglycoside | MDR enterobacteriaceae and S. aureus, including aminoglycoside-resistant and metallo-ß-lactamase producers | cUTI, cIAI | II |
Radezolid | Oxazolidinone | Gram-positive | CAP, SSTI | II |
Razupenem | Carbapenem | Gram-negative and Gram-positive | cSSSIs | II |
Solithromycin | Gram-positive | CAP | III | |
Tebipenem/pivoxil | Carbapenem | Gram-positive and Gram-negative | otolaryngological/RTI | II |
Tedizolidphosphate | Oxazolidinone | Gram-positive, including MRSA | cSSSIs | III |
Telavancin | Glycopeptide | Gram-positive | cSSTI, HAP, VAP | Approved by FDA and EMA |
Tomopenem | Carbapenem | Gram-positive, including MRSA and Gram-negatives including ESBL-producing Enterobacteriaceae | cSSSIs, HAP | II |